A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.

J Neurol · 2023 · PMC10024306 · PMID 36933032

Europe PMC DOI

hedged sentence

0.0789

closest p · 1.6× alpha

0.0789

boldest claim

The sentences

a positive trendp value = 0.0789so close (0.05 < p ≤ 0.1)

We analysed the correlation between the time during which they had been taking ocrelizumab and until they received their second dose of vaccine and the associated T cell response (Ag1 and Ag2) and did not find any significant differences, but there was a positive trend for the t correlation: R 2 = 0.8484, p value = 0.0789 for Ag1 and R 2 = 0.7875, p value = 0.1126 for Ag2.

also in 5,550 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.